RxDoctor Payments Data

Kelly Saltsman, APRN

Family · Columbus, OHNPI 1821694068

Payments from drug & device makers

$3,218in general payments, 2019–2025

Across 27 payments — averaging $119.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Pulmonx Corporation$1K
  • Novartis$198
  • Pfizer$127
  • Bayer$122
  • AstraZeneca$115
  • plus $226 from 3 others

What the payments were for

  • Travel & lodging$1,69053%
  • Food & beverage$1,42844%
  • Education$1003%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific8$1,216
Pulmonx Corporation3$1,214
Novartis7$198
Pfizer2$127
Bayer1$122
AstraZeneca2$115
Bridgebio Pharma, Inc.1$108
Medtronic2$107
Cardiac Dimensions, Inc.1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,218 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$23,321
Medicare patients
131
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol228$206,575
EntrestoSacubitril/Valsartan196$203,345
JardianceEmpagliflozin38$38,931
Torsemide228$7,173
Potassium Chloride96$4,269
Metoprolol Succinate217$3,544
Spironolactone316$2,057
Klor-Con M20Potassium Chloride72$1,411
Furosemide322$1,274
Hydralazine Hcl60$1,090
Carvedilol111$1,025
Eplerenone11$953
Bumetanide17$892
Losartan Potassium68$781
Isosorbide Mononitrate ErIsosorbide Mononitrate26$597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$115$206,575228 claims
NovartisEntresto$198$203,345196 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →